# A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)

> **NCT00769132** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 26 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Comparator: niacin + laropiprant
- **DRUG:** Comparator: niacin
- **DRUG:** Comparator: laropiprant
- **DRUG:** Comparator: placebo

## Key facts

- **NCT ID:** NCT00769132
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08-03
- **Primary completion:** 2007-10-13
- **Final completion:** 2007-11-06
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2019-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00769132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00769132, "A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00769132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*